Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation

Amber B. Clemmons, Arpita S. Gandhi, Benjamin Albrecht, Stephanie Jacobson, Jeremy Mark Pantin

Research output: Contribution to journalArticle

Abstract

Background: Patients immediately post-hematopoietic cell transplantation are at high risk for bacteremia. Judicious prophylactic antimicrobial utilization must balance anticipated benefits (reduction infections) versus risk (bacterial resistance, Clostridium difficile). Objective: To compare infectious outcomes (primary: incidence bacteremia; secondary: febrile neutropenia, C. difficile, susceptibility of bacteremia, time to discharge and 30-day mortality) between hematopoietic cell transplantation who received fluoroquinolone prophylaxis to those who did not. Methods: A local institutional review board-approved retrospective study was conducted on all hematopoietic cell transplantation patients (n = 171) comparing those who received fluoroquinolone prophylaxis (n = 105) to those who did not (n = 66). Data included infectious outcomes and mortality for the first 30 days post-hematopoietic cell transplantation. Chi-squared was performed for categorical variables (GraphPad Software Inc., 2015). Secondary analysis compared outcomes within autologous and allogeneic sub-groups. Results: Bacteremia was significantly lower for the overall cohort receiving fluoroquinolone (median duration eight days) versus those without fluoroquinolone (15.2% vs. 31.8%; P < 0.01). No difference was seen in C. difficile infection (P = 0.81) or 30-day mortality (2.9% vs. 4.5%; P = 0.67). In the autologous sub-group (n = 115), bacteremia was significantly lower in the fluoroquinolone cohort (8.5% vs. 27.3%; P = 0.0069), while no differences were seen in C. difficile infection (P = 1) or 30-day mortality (P = 1). In the allogeneic sub-group (n = 56), there was no difference between those with and without fluoroquinolone in bacteremia (29.4% vs. 40.9%; P = 0.4) or C. difficile (P = 0.72); however, there was a trend toward improved 30-day mortality (2.9% vs. 9.1%; P = 0.55). Conclusions: Fluoroquinolone prophylaxis reduces incidence of bacteremia in autologous hematopoietic cell transplantation without increasing C. difficile after hematopoietic cell transplantation.

Original languageEnglish (US)
Pages (from-to)326-332
Number of pages7
JournalJournal of Oncology Pharmacy Practice
Volume25
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Fluoroquinolones
Cell Transplantation
Bacteremia
Clostridium difficile
Mortality
Clostridium Infections
Febrile Neutropenia
Research Ethics Committees
Incidence
Software
Retrospective Studies
Infection

Keywords

  • Bacterial infections
  • bone marrow transplantation
  • fluoroquinolone
  • prophylaxis

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation. / Clemmons, Amber B.; Gandhi, Arpita S.; Albrecht, Benjamin; Jacobson, Stephanie; Pantin, Jeremy Mark.

In: Journal of Oncology Pharmacy Practice, Vol. 25, No. 2, 01.03.2019, p. 326-332.

Research output: Contribution to journalArticle

Clemmons, Amber B. ; Gandhi, Arpita S. ; Albrecht, Benjamin ; Jacobson, Stephanie ; Pantin, Jeremy Mark. / Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation. In: Journal of Oncology Pharmacy Practice. 2019 ; Vol. 25, No. 2. pp. 326-332.
@article{8957ea01dc8c4d7b88d0fc023afdff2d,
title = "Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation",
abstract = "Background: Patients immediately post-hematopoietic cell transplantation are at high risk for bacteremia. Judicious prophylactic antimicrobial utilization must balance anticipated benefits (reduction infections) versus risk (bacterial resistance, Clostridium difficile). Objective: To compare infectious outcomes (primary: incidence bacteremia; secondary: febrile neutropenia, C. difficile, susceptibility of bacteremia, time to discharge and 30-day mortality) between hematopoietic cell transplantation who received fluoroquinolone prophylaxis to those who did not. Methods: A local institutional review board-approved retrospective study was conducted on all hematopoietic cell transplantation patients (n = 171) comparing those who received fluoroquinolone prophylaxis (n = 105) to those who did not (n = 66). Data included infectious outcomes and mortality for the first 30 days post-hematopoietic cell transplantation. Chi-squared was performed for categorical variables (GraphPad Software Inc., 2015). Secondary analysis compared outcomes within autologous and allogeneic sub-groups. Results: Bacteremia was significantly lower for the overall cohort receiving fluoroquinolone (median duration eight days) versus those without fluoroquinolone (15.2{\%} vs. 31.8{\%}; P < 0.01). No difference was seen in C. difficile infection (P = 0.81) or 30-day mortality (2.9{\%} vs. 4.5{\%}; P = 0.67). In the autologous sub-group (n = 115), bacteremia was significantly lower in the fluoroquinolone cohort (8.5{\%} vs. 27.3{\%}; P = 0.0069), while no differences were seen in C. difficile infection (P = 1) or 30-day mortality (P = 1). In the allogeneic sub-group (n = 56), there was no difference between those with and without fluoroquinolone in bacteremia (29.4{\%} vs. 40.9{\%}; P = 0.4) or C. difficile (P = 0.72); however, there was a trend toward improved 30-day mortality (2.9{\%} vs. 9.1{\%}; P = 0.55). Conclusions: Fluoroquinolone prophylaxis reduces incidence of bacteremia in autologous hematopoietic cell transplantation without increasing C. difficile after hematopoietic cell transplantation.",
keywords = "Bacterial infections, bone marrow transplantation, fluoroquinolone, prophylaxis",
author = "Clemmons, {Amber B.} and Gandhi, {Arpita S.} and Benjamin Albrecht and Stephanie Jacobson and Pantin, {Jeremy Mark}",
year = "2019",
month = "3",
day = "1",
doi = "10.1177/1078155217735153",
language = "English (US)",
volume = "25",
pages = "326--332",
journal = "Journal of Oncology Pharmacy Practice",
issn = "1078-1552",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Impact of fluoroquinolone prophylaxis on infectious-related outcomes after hematopoietic cell transplantation

AU - Clemmons, Amber B.

AU - Gandhi, Arpita S.

AU - Albrecht, Benjamin

AU - Jacobson, Stephanie

AU - Pantin, Jeremy Mark

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Patients immediately post-hematopoietic cell transplantation are at high risk for bacteremia. Judicious prophylactic antimicrobial utilization must balance anticipated benefits (reduction infections) versus risk (bacterial resistance, Clostridium difficile). Objective: To compare infectious outcomes (primary: incidence bacteremia; secondary: febrile neutropenia, C. difficile, susceptibility of bacteremia, time to discharge and 30-day mortality) between hematopoietic cell transplantation who received fluoroquinolone prophylaxis to those who did not. Methods: A local institutional review board-approved retrospective study was conducted on all hematopoietic cell transplantation patients (n = 171) comparing those who received fluoroquinolone prophylaxis (n = 105) to those who did not (n = 66). Data included infectious outcomes and mortality for the first 30 days post-hematopoietic cell transplantation. Chi-squared was performed for categorical variables (GraphPad Software Inc., 2015). Secondary analysis compared outcomes within autologous and allogeneic sub-groups. Results: Bacteremia was significantly lower for the overall cohort receiving fluoroquinolone (median duration eight days) versus those without fluoroquinolone (15.2% vs. 31.8%; P < 0.01). No difference was seen in C. difficile infection (P = 0.81) or 30-day mortality (2.9% vs. 4.5%; P = 0.67). In the autologous sub-group (n = 115), bacteremia was significantly lower in the fluoroquinolone cohort (8.5% vs. 27.3%; P = 0.0069), while no differences were seen in C. difficile infection (P = 1) or 30-day mortality (P = 1). In the allogeneic sub-group (n = 56), there was no difference between those with and without fluoroquinolone in bacteremia (29.4% vs. 40.9%; P = 0.4) or C. difficile (P = 0.72); however, there was a trend toward improved 30-day mortality (2.9% vs. 9.1%; P = 0.55). Conclusions: Fluoroquinolone prophylaxis reduces incidence of bacteremia in autologous hematopoietic cell transplantation without increasing C. difficile after hematopoietic cell transplantation.

AB - Background: Patients immediately post-hematopoietic cell transplantation are at high risk for bacteremia. Judicious prophylactic antimicrobial utilization must balance anticipated benefits (reduction infections) versus risk (bacterial resistance, Clostridium difficile). Objective: To compare infectious outcomes (primary: incidence bacteremia; secondary: febrile neutropenia, C. difficile, susceptibility of bacteremia, time to discharge and 30-day mortality) between hematopoietic cell transplantation who received fluoroquinolone prophylaxis to those who did not. Methods: A local institutional review board-approved retrospective study was conducted on all hematopoietic cell transplantation patients (n = 171) comparing those who received fluoroquinolone prophylaxis (n = 105) to those who did not (n = 66). Data included infectious outcomes and mortality for the first 30 days post-hematopoietic cell transplantation. Chi-squared was performed for categorical variables (GraphPad Software Inc., 2015). Secondary analysis compared outcomes within autologous and allogeneic sub-groups. Results: Bacteremia was significantly lower for the overall cohort receiving fluoroquinolone (median duration eight days) versus those without fluoroquinolone (15.2% vs. 31.8%; P < 0.01). No difference was seen in C. difficile infection (P = 0.81) or 30-day mortality (2.9% vs. 4.5%; P = 0.67). In the autologous sub-group (n = 115), bacteremia was significantly lower in the fluoroquinolone cohort (8.5% vs. 27.3%; P = 0.0069), while no differences were seen in C. difficile infection (P = 1) or 30-day mortality (P = 1). In the allogeneic sub-group (n = 56), there was no difference between those with and without fluoroquinolone in bacteremia (29.4% vs. 40.9%; P = 0.4) or C. difficile (P = 0.72); however, there was a trend toward improved 30-day mortality (2.9% vs. 9.1%; P = 0.55). Conclusions: Fluoroquinolone prophylaxis reduces incidence of bacteremia in autologous hematopoietic cell transplantation without increasing C. difficile after hematopoietic cell transplantation.

KW - Bacterial infections

KW - bone marrow transplantation

KW - fluoroquinolone

KW - prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85060401597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060401597&partnerID=8YFLogxK

U2 - 10.1177/1078155217735153

DO - 10.1177/1078155217735153

M3 - Article

C2 - 29059026

AN - SCOPUS:85060401597

VL - 25

SP - 326

EP - 332

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

SN - 1078-1552

IS - 2

ER -